Article Text
PDFBrief report
A European consistency for functioning of RECs? We just lost our chance
Abstract
On 17 July 2012, the European Commission formally adopted a proposal for a new European Union (EU) Directive regarding clinical trials, which will repeal and replace the existing Directive 2001/20/EC. The main reasons for the revision were: (1) the decreasing number of clinical trials in the region and (2) harsh criticism of the present version of the Directive. The proposed regulation could simplify the rules for conducting clinical trials and also rebuild the entire system of clinical trial assessment. However, it seems that we probably have already lost our chance regarding the consistency and quality of functioning of research ethics committees in the EU.
- Clinical trials
- Commissions/Councils
- Drugs and Drug Industry
- Ethics Committees/Consultation
- Research Ethics
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Implementation of the EU clinical trial regulation transforms the ethics committee systems and endangers ethical standards
- Research ethics committees in Europe: implementing the directive, respecting diversity
- Multicentre trials review process by research ethics committees in Spain: where do they stand before implementing the new European regulation?
- Legislative regulation and ethical governance of medical research in different European Union countries
- The EU Clinical Trials Regulation: key priorities, purposes and aims and the implications for public health
- Gender equality in the work of local research ethics committees in Europe: a study of practice in five countries
- Learning from MARQuIS: future direction of quality and safety in hospital care in the European Union
- News from the European Union
- Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities
- EU News